Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice

Kim, 2010, Incidence, epidemiology and patterns of progression of prostate cancer, J Korean Med Assoc, 53, 92, 10.5124/jkma.2010.53.2.92 Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506 de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618 de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720 Petrylak, 2004, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, 351, 1513, 10.1056/NEJMoa041318 Eymard, 2010, Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study, BJU Int, 106, 974, 10.1111/j.1464-410X.2010.09296.x Loriot, 2010, The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer, Eur J Cancer, 46, 1770, 10.1016/j.ejca.2010.04.010 Di Lorenzo, 2011, Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer, BJU Int, 107, 234, 10.1111/j.1464-410X.2010.09498.x Scher, 2004, Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group, J Clin Oncol, 22, 537, 10.1200/JCO.2004.07.099 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487 Smith, 1998, Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer, J Clin Oncol, 16, 1835, 10.1200/JCO.1998.16.5.1835 Petrylak, 2006, Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16, J Natl Cancer Inst, 98, 516, 10.1093/jnci/djj129 Armstrong, 2010, Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer, Clin Cancer Res, 16, 203, 10.1158/1078-0432.CCR-09-2514 Joung, 2008, Docetaxel chemotherapy of Korean patients with hormone-refractory prostate cancer:comparative analysis between 1st-line and 2nd-line docetaxel, Yonsei Med J, 49, 775, 10.3349/ymj.2008.49.5.775 Lee, 2010, Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea, Cancer Res Treat, 42, 12, 10.4143/crt.2010.42.1.12 Berthold, 2008, Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study, Clin Cancer Res, 14, 2763, 10.1158/1078-0432.CCR-07-0944 Berthold, 2008, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study, J Clin Oncol, 26, 242, 10.1200/JCO.2007.12.4008 Mountzios, 2011, Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer, Urology, 77, 682, 10.1016/j.urology.2010.08.044 Caffo, 2012, Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors, Urology, 79, 644, 10.1016/j.urology.2011.11.043 Heck, 2012, Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer, BJU Int, 110, E635, 10.1111/j.1464-410X.2012.11364.x Miyoshi, 2005, Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients, Int J Clin Oncol, 10, 182, 10.1007/s10147-005-0490-0 Akaza, 2007, The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy, Asian Pac J Cancer Prev, 8, 3